Drug Profile
Irinotecan-eluting beads - Biocompatibles
Alternative Names: CM-BC2; DEBIRI; Irinotecan bead; Irinotecan-loaded DC Bead LUMI™; Irinotecan-loaded DC BeadM1™; Irinotecan-loaded DC Bead™; PARAGON BeadLatest Information Update: 17 Dec 2021
Price :
$50
*
At a glance
- Originator Biocompatibles International
- Developer Biocompatibles International; BTG; Singapore General Hospital
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Colorectal cancer; Liver metastases
- Phase II Cholangiocarcinoma
- Phase I/II Glioma
Most Recent Events
- 17 Dec 2020 BTG International terminates a phase I/II trial in Glioma (Adjunctive treatment, Recurrent) in Germany and France based on the slow rate of recruitment across the programme of studies (NCT02481960)
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 19 Oct 2018 Safety and efficacy data from a phase II trial in Colorectal cancer with liver metastases presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018) (NCT01839877)